ClinicalTrials.gg
CompletedNCT03104595Updated Nov 4, 2026Results posted

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

A Phase 1/2 interventional study of EC-18 in Febrile Neutropenia, sponsored by Enzychem Lifesciences Corporation. Completed at 3 sites in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Enzychem Lifesciences Corporation · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
19 Years and older
Sex
Female
01

Study summary

To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.

Read the detailed description

This study will utilize a non-randomized, open-label 3 + 3 dose escalation design in which subjects will receive 500 mg, 1000 mg, 1500 mg, 2000 mg, 3000 mg and 4000mg of EC-18. The stepwise daily dosing by cohort was performed for 21 days (3 weeks)

02

Conditions studied

  • Febrile Neutropenia

Keywords

  • EC-18, febrile neutropenia, breast cancer, chemotherapy
03

In context

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

This study's enrollment of 28 is below the median of 120 across 95 interventional studies indexed under Febrile Neutropenia.

Browse Febrile Neutropenia studies →

Lead sponsor

Enzychem Lifesciences Corporation is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women ≥19 years of age
  2. Subjects who have voluntarily signed the prior to the screening tests to participate in the study
  3. Subjects who have been diagnosed as adenocarcinoma of the breast and after or primary (neoadjuvant) chemotherapy, and was confirmed based on documented medical history to be candidates for or higher combination chemotherapy with doxorubicin and cyclophosphamide to treat relapsed or disease.
  4. Subjects with adequate function of major organs based on the following clinical laboratory values in the latest test performed within 28 days prior to IP dosing:

    • (ANC): ≥1,500/mm3
    • count: ≥10.0×10\^4/mm3
    • : ≥9.0 g/dL
    • , ALT: ≤3.0 x
    • Serum total : ≤1.5 mg/dL
    • Serum creatinine: ≤1.5 mg/dL
  5. Subjects whose (ECOG) performance score is 0-1.
  6. For women of child bearing potential, subjects should have willingness to use acceptable methods during the entire clinical study period.
  7. Subjects who are capable of understanding the overall procedure of the clinical study and are willing to participate in compliance with all test procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with active and inactive hepatitis, patients with history of , or other uncontrolled infectious disease.
  2. Subjects with a history of HIV positive or currently undergoing/received antiretroviral therapy, and subjects with a history of surface antigen positive, or current positive disease.
  3. Subjects who received radiation therapy within 4 weeks prior to assignment to treatment group.
  4. Subjects who have been diagnosed within 5 years with other types of cancer except for those who have been appropriately treated for superficial non-melanoma skin cancer or cervical intraepithelial neoplasia.
  5. Subjects with a history of intolerance for granulocyte colony stimulating factor treatment
  6. Subjects who are expected to show to the IP or its ingredients
  7. Subjects with a positive urine pregnancy test result at screening visit or before the first administration of the study drug
  8. Subjects who took any other product in other clinical study within 30 days prior to screening visit.
  9. unstable medical abnormality; psychiatric disorder, chronic disease, alcohol or drug use disorder, or other significant biological, psychological, or social factor, which in the investigator's opinion, unfavorably affects the risk-benefit ratio of study participation or likely to affect study results.
  10. Subjects with heart disease (i.e. congestive heart failure, arrhythmia, symptomatic coronary artery disease); Myocardial infarction within 6 months before initiation of the study.
  11. Subjects with (LVEF) \< 50% at screening.
  12. Significant neurological or psychiatric disorders including dementia or seizures.
  13. Patients with dyslipidemia not controlled by drugs [based on LDL-C and TG levels for which treatment is recommended by the Korean dyslipidemia treatment guidelines and the U.S. National Cholesterol Education Program-Adult Treatment Panel III]
  14. Uncontrolled diabetes mellitus ( >7%; if the level is confirmed after 6 months or longer treatment with oral hypoglycemic agents or insulin)
  15. Subjects who have received systemic chemotherapy with doxorubicin to treat or recurrent breast cancer
  16. Subjects with grade 2 or higher peripheral sensory neuropathy at screening visit or before the first dosing of the study drug
  17. Subjects who have undergone significant gastrectomy along with intractable nausea and vomiting, chronic gastrointestinal disease, or clinically significant sequelae, which would interfere with proper absorption of the study drug
  18. Subjects who administered systemic antibiotics within 14 days prior to administration of the study drug
  19. Subjects whose cumulative dose of doxorubicin exceeded 240 mg/m2
  20. Subjects who were currently receiving trastuzumab
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1

    EC-18 500 mg

    Drug: EC-18

  • Experimental
    Cohort 2

    EC-18 1000 mg

    Drug: EC-18

  • Experimental
    Cohort 3

    EC-18 1500 mg

    Drug: EC-18

  • Experimental
    Cohort 4

    EC-18 2000 mg

    Drug: EC-18

  • Experimental
    Cohort 5

    EC-18 3000 mg

    Drug: EC-18

  • Experimental
    Cohort 6

    EC-18 4000 mg

    Drug: EC-18

Interventions

06

What researchers measure

Primary outcomes

  1. Duration of Grade 4 Neutropenia

    Duration of Grade 4 neutropenia during Cycle 1 of chemotherapy, based on absolute neutrophil count (ANC) assessed using NCI CTCAE v4.03.

    Time frame: During Cycle 1 of chemotherapy (up to 21 days)

Secondary outcomes

  1. Number of Participants With Grade 3-4 Neutropenia

    Neutropenia was graded according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced Grade 3 or Grade 4 neutropenia during Cycle 1 of chemotherapy.

    Time frame: During Cycle 1 of chemotherapy

  2. Number of Participants With Febrile Neutropenia

    Febrile neutropenia was assessed based on absolute neutrophil count (ANC) and body temperature according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced febrile neutropenia during the study period.

    Time frame: For 15 days after starting chemotherapy (except for Days 3 and 4).

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were assessed from initiation of EC-18 treatment through the end of the final follow-up period. This outcome reports the number of participants who experienced at least one TEAE. Adverse events were graded according to NCI CTCAE v4.03.

    Time frame: From first dose of EC-18 through the final safety follow-up visit (3-week treatment period and follow-up visit at Day 36)

  2. Clinical Laboratory Evaluations

    Clinical laboratory tests (hematology, clinical chemistry, coagulation, and urine test result analysis) -- absolute values and changes from the baseline

    Time frame: 3-week treatment period and follow-up visit at day 36

  3. Vital Signs

    Absolute values and changes from baseline in vital signs

    Time frame: 3-week treatment period and follow-up visit at day 36

  4. 12-lead Electrocardiogram (ECG)

    Absolute values and changes from baseline ECG

    Time frame: 3-week treatment period and follow-up visit

07

Results

Posted Nov 4, 2026

Participant flow

This clinical study was conducted in women with advanced breast cancer receiving low febrile neutropenia risk chemotherapy.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Started734644
Completed333313
Not completed401331

Outcome measures

PrimaryDuration of Grade 4 Neutropenia

Duration of Grade 4 neutropenia during Cycle 1 of chemotherapy, based on absolute neutrophil count (ANC) assessed using NCI CTCAE v4.03.

Time frame:
During Cycle 1 of chemotherapy (up to 21 days)
Reported as:
Mean · Days
Duration of Grade 4 Neutropenia
DaysCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Duration of Grade 4 Neutropenia4.8 ± 1.96.0 ± 2.64.0 ± 2.24.2 ± 1.34.3 ± 1.54.8 ± 1.7
SecondaryNumber of Participants With Grade 3-4 Neutropenia

Neutropenia was graded according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced Grade 3 or Grade 4 neutropenia during Cycle 1 of chemotherapy.

Time frame:
During Cycle 1 of chemotherapy
Reported as:
Count of participants · Participants
Number of Participants With Grade 3-4 Neutropenia
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Number of Participants With Grade 3-4 Neutropenia634634
SecondaryNumber of Participants With Febrile Neutropenia

Febrile neutropenia was assessed based on absolute neutrophil count (ANC) and body temperature according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced febrile neutropenia during the study period.

Time frame:
For 15 days after starting chemotherapy (except for Days 3 and 4).
Reported as:
Count of participants · Participants
Number of Participants With Febrile Neutropenia
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Number of Participants With Febrile Neutropenia401331
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) were assessed from initiation of EC-18 treatment through the end of the final follow-up period. This outcome reports the number of participants who experienced at least one TEAE. Adverse events were graded according to NCI CTCAE v4.03.

Time frame:
From first dose of EC-18 through the final safety follow-up visit (3-week treatment period and follow-up visit at Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Number of Participants With Treatment-Emergent Adverse Events734644
Other pre-specifiedClinical Laboratory Evaluations

Clinical laboratory tests (hematology, clinical chemistry, coagulation, and urine test result analysis) -- absolute values and changes from the baseline

Time frame:
3-week treatment period and follow-up visit at day 36

No measurements were reported for this outcome.

Other pre-specifiedVital Signs

Absolute values and changes from baseline in vital signs

Time frame:
3-week treatment period and follow-up visit at day 36

No measurements were reported for this outcome.

Other pre-specified12-lead Electrocardiogram (ECG)

Absolute values and changes from baseline ECG

Time frame:
3-week treatment period and follow-up visit

No measurements were reported for this outcome.

Adverse events

Collected over From screening until the end of follow up at day 36 +/- 2 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/7 (0%)4/7 (57.1%)7/7 (100%)
Cohort 20/3 (0%)0/3 (0%)3/3 (100%)
Cohort 30/4 (0%)1/4 (25%)4/4 (100%)
Cohort 40/6 (0%)2/6 (33.3%)6/6 (100%)
Cohort 50/4 (0%)2/4 (50%)4/4 (100%)
Cohort 60/4 (0%)1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Febrile NeutropeniaBlood and lymphatic system disorders4/70/31/42/62/40/4
NeutropeniaBlood and lymphatic system disorders0/70/30/40/60/41/4
Most frequent other events
Showing 10 of 35
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Neutrophil count decreasedInvestigations6/73/33/45/61/42/4
FatigueGeneral disorders6/72/30/41/63/40/4
Febrile neutropeniaBlood and lymphatic system disorders4/70/31/43/63/41/4
NauseaGastrointestinal disorders2/72/32/42/63/43/4
ConstipationGastrointestinal disorders0/70/30/44/61/41/4
StomatitisGastrointestinal disorders4/72/30/41/60/42/4
Decreased appetiteMetabolism and nutrition disorders3/72/30/40/60/41/4
DizzinessNervous system disorders1/72/30/40/60/41/4
MyalgiaMusculoskeletal and connective tissue disorders1/70/32/40/62/40/4
AlopeciaSkin and subcutaneous tissue disorders3/70/32/42/60/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Mean55.7 ± 6.949.3 ± 0.656.5 ± 6.257.3 ± 10.556.0 ± 7.554.5 ± 5.555.4 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Female73464428
Male0000000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Count of participants——————0
08

Study locations

3 sites
  • National Cancer Center
    Gyeonggi-do, Gyeonggi-do 10408, South Korea
  • Yonsei University Health System Severance Hospital
    Seoul, Seoul 03722, South Korea
  • Asan Medical Center
    Seoul, Seoul 05505, South Korea
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Nov 2019, 24 months.

Results were first posted in Nov 2026, 6 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2017
First posted
Apr 7, 2017
StartActual
Oct 30, 2017
Primary completionActual
Nov 26, 2019
CompletionActual
Dec 5, 2019
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Sites
3 sites added, 3 sites removed — first site in South Korea; no longer in Korea, Republic of
Show 3 added (3 South Korea)
  • National Cancer Center · Gyeonggi-do, South Korea
  • Yonsei University Health System Severance Hospital · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
Show 3 removed
  • National Cancer Center · Gyeonggi-do, Korea, Republic of
  • Yonsei University Health System Severance Hospital · Seoul, Korea, Republic of
  • Asan Medical Center · Seoul, Korea, Republic of
Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedDuration of Grade 4 neutropeniaNeutropeniaTime frame: 15 days after starting chemotherapy → During Cycle 1 of chemotherapy (up to 21 days)
Nov 4, 2026
Documents
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedIncidenceNumber of Participants With Grade 3-4 neutropeniaNeutropeniaTime frame: For 15 days after starting chemotherapy (except Day 3 and 4) → During Cycle 1 of chemotherapy
  • EditedIncidenceNumber of febrile neutropeniaParticipants With Febrile NeutropeniaTime frame: For 15 days after starting chemotherapy (except Day 3 and 4) → For 15 days after starting chemotherapy (except for Days 3 and 4).
  • Editedother outcomeClinical laboratory evaluationsLaboratory EvaluationsTime frame: 3-week treatment period and follow-up visit at day 36
  • Editedother outcomeVital signsSignsTime frame: 3-week treatment period and follow-up visit at day 36
  • Editedother outcome12-lead electrocardiogramElectrocardiogram (ECG)Time frame: 3-week treatment period and follow-up visit at day 36 → 3-week treatment period and follow-up visit
  • Changedother outcomeBefore Incidence of adverse eventsNow Number of Participants With Treatment-Emergent Adverse EventsTime frame: 3-week treatment period and follow-up visit at day 36 → From first dose of EC-18 through the final safety follow-up visit (3-week treatment period and follow-up visit at Day 36)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    3 sites added, 3 sites removed — first site in South Korea; no longer in Korea, Republic of
    Show 3 added (3 South Korea)
    • National Cancer Center · Gyeonggi-do, South Korea
    • Yonsei University Health System Severance Hospital · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    Show 3 removed
    • National Cancer Center · Gyeonggi-do, Korea, Republic of
    • Yonsei University Health System Severance Hospital · Seoul, Korea, Republic of
    • Asan Medical Center · Seoul, Korea, Republic of
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedDuration of Grade 4 neutropeniaNeutropeniaTime frame: 15 days after starting chemotherapy → During Cycle 1 of chemotherapy (up to 21 days)
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedIncidenceNumber of Participants With Grade 3-4 neutropeniaNeutropeniaTime frame: For 15 days after starting chemotherapy (except Day 3 and 4) → During Cycle 1 of chemotherapy
    • EditedIncidenceNumber of febrile neutropeniaParticipants With Febrile NeutropeniaTime frame: For 15 days after starting chemotherapy (except Day 3 and 4) → For 15 days after starting chemotherapy (except for Days 3 and 4).
    • Editedother outcomeClinical laboratory evaluationsLaboratory EvaluationsTime frame: 3-week treatment period and follow-up visit at day 36
    • Editedother outcomeVital signsSignsTime frame: 3-week treatment period and follow-up visit at day 36
    • Editedother outcome12-lead electrocardiogramElectrocardiogram (ECG)Time frame: 3-week treatment period and follow-up visit at day 36 → 3-week treatment period and follow-up visit
    • Changedother outcomeBefore Incidence of adverse eventsNow Number of Participants With Treatment-Emergent Adverse EventsTime frame: 3-week treatment period and follow-up visit at day 36 → From first dose of EC-18 through the final safety follow-up visit (3-week treatment period and follow-up visit at Day 36)
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03104595
Lead sponsor
Enzychem Lifesciences Corporation
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Oct 30, 2017
Primary completion
Nov 26, 2019
Completion
Dec 5, 2019
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Sung-Bae Kim, MD, PhD
principal investigator · Asan Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosedipimod

Start the discussion